Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy
15.9.2022 15:02:00 EEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
Contact information
Biocytogen
Platform and Assets:
BD-Licensing@biocytogen.com
Media:
pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Unveils Budget Clarity AI, Giving Every Finance and IT Leader a Financial Analyst at the Tip of Their Fingers29.9.2026 17:18:00 EEST | Press release
Brightfin, the leader in technology financial management, today announced Budget Clarity AI, a new capability that gives finance and IT teams instant, self-service answers to the budget questions they field dozens of times a day. Built into the Brightfin platform, Budget Clarity AI acts as an always-available financial analyst, letting users ask plain-language questions about their spend and get grounded answers, visualizations, and recommendations in seconds. Finance and IT leaders are fielding an ever-growing volume of ad-hoc budget questions from stakeholders across the business, while the analysts who could answer them are stretched thin. Budget Clarity AI is designed to close that gap. Users don't need to know ServiceNow, and they don't need to know Brightfin's products — they only need to know what they're trying to get done, and the tool routes them to the answer in one click. What Budget Clarity AI Delivers A simplified experience: users don't need to know ServiceNow or Brightf
Laserfiche Names Garrett Boss as CIO to Lead Enterprise IT, Security, and Business Transformation29.9.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced the appointment of Garrett Boss as chief information officer. Boss will oversee Laserfiche’s global IT services team and business transformation office, including deployment of internal Laserfiche solutions and all other enterprise-wide IT systems. In this role, he will also oversee governance, risk, and compliance, supporting Laserfiche's mission to scale AI innovation while safeguarding the critical content and lifecycle tools customers rely on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929335686/en/ Garrett Boss joins Laserfiche as chief information officer. “Laserfiche’s own technology infrastructure and security posture are central to how we deliver an exceptional product and responsive services,” said CEO Karl Chan. “Garrett is a proven leader with a track record of leading global IT and go
Andersen Global Strengthens Argentina Presence with Fidem Partners29.9.2026 16:30:00 EEST | Press release
Andersen Global expands its tax and transaction capabilities in Argentina through a Collaboration Agreement with Fidem Partners, strengthening its presence and service offerings in the market. Established in 2011, Fidem Partners advises businesses on tax and compliance, M&A, and business process outsourcing. The firm serves companies across the energy, technology, financial services, agribusiness, and consumer goods sectors with deep experience serving subsidiaries of multinational companies in Argentina. Its multidisciplinary team draws on experience from leading professional services firms and business environments to provide practical guidance throughout the key stages of the business lifecycle. "Most of our work is with subsidiaries of multinational companies operating in Argentina, where the regulatory environment demands judgment, not just compliance," said Darío H. Díaz, managing partner of Fidem Partners. "Collaborating with Andersen Global gives our clients access to a global
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 16:00:00 EEST | Press release
Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligent Market Intelligence. “Boards are also increasingly viewing CEOs as a scarce global talent pool.” CEO turnover drives higher transition costs Cash sign-on bonuses for new S&P
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 16:00:00 EEST | Press release
Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by giving users a way to make the output from their AI tools visual, immediately editable, and accessible to the whole team on a shared canvas. Miro user data shows Claude
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom